NICE National Institute for Health and Care Excellence

Economic plan

This plan identifies the areas prioritised for economic modelling. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline.

1 Guideline

Hypertension in adults: diagnosis and management

2 List of modelling questions

Review question by scope area	At what blood pressure and/or cardiovascular disease risk threshold should antihypertensive drug treatment be initiated for adults with hypertension?
Population	Adults with primary stage 1 hypertension, who do not have target organ damage, established cardiovascular disease (CVD), renal disease or diabetes. Base case age of 60. The comparators were compared in the following 10-year QRISK2 cardiovascular risk subgroups: • 5% • 10% • 15% • 20% Men and women analysed separately, and alternative starting ages of 40, 50, 70, and 75 were also explored.
Interventions and comparators considered for inclusion	• Antihypertensive drug treatment • No antihypertensive drug treatment
Perspective	Intervention with health outcomes in NHS setting (UK NHS and PSS costs)
Outcomes	Cost per QALY gained, number of cardiovascular events.
Type of analysis	Cost-utility analysis
Issues to note	

Review question by scope area	In people with suspected hypertension, which test is most accurate in identifying whether hypertension is present, as indicated by the reference standard, ambulatory blood pressure measurement?

4.0.04 DOC Economic Plan

Population	People with suspected hypertension – those with a screening clinic blood pressure measurement equal or above 140/90 mmHg. Men and women analysed separately, and starting ages of 40, 50, 60, 70, and 75 were explored.
Interventions and comparators considered for inclusion	• Clinic blood pressure monitoring (CBPM) • Home blood pressure monitoring (HBPM) • Ambulatory blood pressure monitoring (ABPM)
Perspective	Intervention with health outcomes in NHS setting (UK NHS and PSS costs)
Outcomes	Cost per QALY gained, number of cardiovascular events.
Type of analysis	Cost-utility analysis
Issues to note	This was a minor update to the 2011 hypertension guideline original model on diagnosis of hypertension, with a new analysis added which involved only adding in new diagnostic accuracy data.